Title Page

Title : Plasma von Willebrand factor levels predict in – hospital survival in patients with acute on chronic liver failure

Authors : K.S. Prasanna[1], Ashish Goel[1], G. Jayakumar Amirtharaj[2], Anup Ramachandran[2], K.A Balasubramanian[2], Ian Mackie[3], Uday Zachariah[1], K.G Sajith[1], Elwyn Elias[1,4], C.E Eapen[1]

Affiliations : Departments of Hepatology[1] and Wellcome Biochemistry[2], Christian Medical College, Vellore, Tamil Nadu, India; Haemostasis Research Unit, Haematology Department, University College London, London, UK[3]; Emeritus Professor, Liver Unit, University Hospital Birmingham, Birmingham, UK[4]

Email IDs :

K.S.Prasanna : prasannaks19@gmail.com

Ashish Goel : drashishgoel@cmcvellore.ac.in

G. Jayakumar Amirtharaj : gjayakumar@cmcvellore.ac.in

Anup Ramachandran : anup@cmcvellore.ac.in

K.A.Balasubramanian : wlbalu@hotmail.com

Ian Mackie : i.mackie@ucl.ac.uk

Uday Zachariah : udayzachariah@cmcvellore.ac.in

K.G.Sajith : drsaji@yahoo.com

Elwyn Elias : elwyn.elias@gmail.com

C.E.Eapen : eapen@cmcvellore.ac.in

Corresponding author :

Dr. C.E.Eapen

Department of Hepatology,

Christian Medical College, Vellore-632004

Tamil Nadu, India

Tel : +91-416-2282148 (O); Fax : +91-416-2232035

Email : eapen@cmcvellore.ac.in

List of Abbreviations :

vWF : von-Willebrand Factor

ACLF : Acute on Chronic Liver failure

SIRS : Systemic Inflammatory response Syndrome

MELD : Model for End-stage Liver Disease

SOFA: Sequential Organ Failure Assessment

ADAMTS13 : A disintegrin and metalloprotease with thrombospondin type 1 motif, member 13

APASL : Asia-Pacific Association for the Study of the Liver

EASL-CLIF consortium : European Association for the Study of the Liver- Chronic Liver Failure consortium

Financial Support : We gratefully acknowledge funding support received from Department of Science and Technology, Government of India (File No. EMR/2015/000570) and FLUID research funds, Christian Medical College, Vellore, India towards the conduct of this study.

Contributions by authors :

	Concept	Design	Data	Analysis	Draft	Revision	Approval	Techincal
KSP	√	√	√	√	√	√	√	√
AG	√	√	√	√	√	√	√	√
GJA	√	√	√	-	√	√	√	√
AR	√	√	√	-	-	√	√	√
KAB	√	√	-	-		√	√	-
IM	√	-	-	-	-	√	√	√
UZ	√	√	√	-	-	√	√	√
KGS	√	√	-	-	-	-	√	-
EE	√	√	-	-	-	√	√	-
CEE	√	√	√	√	√	√	√	√

Plasma von-Willebrand factor levels predict in – hospital survival in patients with acute on chronic liver failure

Abstract :

Background and Aims : Circulating levels of von Willebrand factor (vWF) predict mortality in patients with cirrhosis. We hypothesised that systemic inflammation in acute on chronic liver failure (ACLF) will stimulate endothelium, increase vWF levels and promote platelet microthombi causing organ failure.

Methods : In this prospective study, we correlated plasma vWF levels with organ failure, liver disease severity, sepsis and systemic inflammatory response syndrome (SIRS) and also analysed if vWF levels predicted in-hospital composite poor outcome (i.e. death/discharged in terminal condition/liver transplantation) in consecutive ACLF patients.

Results : 21of the 50 ACLF patients studied, had composite poor outcome. ACLF patients had markedly elevated vWF antigen and activity (7 fold and 5 fold median increase, respectively) on Days 1 and 3. Median ratio of vWF to ADAMTS13 activity on Day 1 was significantly higher in ACLF patients (11.2) compared to 20 compensated cirrhosis patients (3.3) and healthy volunteers (0.9). On Day 1, AUROC to predict composite poor outcome of hospital stay for ACLF patients for vWF antigen, vWF activity and MELD score were 0.63, 0.68 and 0.74, respectively. vWF activity correlated better with liver disease severity (MELD score, ACLF grade) and organ failure (SOFA score) than vWF antigen; in contrast, neither vWF antigen nor activity correlated with platelet count, sepsis or SIRS.

Conclusions: vWF levels are markedly elevated, correlate with organ failure and predict in–hospital survival in ACLF patients. This data provides a mechanistic basis for postulating that vWF-reducing treatments such as plasma exchange may benefit ACLF patients.

Keywords.: ACLF, endothelial activation, vWF, ADAMTS13

Introduction

Acute on chronic liver failure (ACLF) is associated with high (50-90%) short and medium - term mortality[1]. Increasing grade of ACLF (ie: increasing numbers of organs failing)[2] is a strong predictor of short term mortality[3]. The high mortality in ACLF is mainly attributed to unregulated systemic inflammation, causing (both hepatic and extra-hepatic) organ failure[2,4]. Presence of systemic inflammatory response syndrome (SIRS) predicts development of ACLF in patients with alcoholic liver disease[5].

In critically ill patients, SIRS contributes to disseminated intravascular coagulation, development of microvascular thrombosis (varying from 20% to 100% depending on the organ studied) and consequent multi-organ failure [6]. von Willebrand factor (vWF), released from activated endothelium in very high molecular weight forms, is an adhesive protein to which platelets stick. In patients with sepsis, development of organ failure and systemic inflammation is linked to imbalance of vWF – ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13) : high vWF levels and low levels of ADAMTS13 (a vWF cleaving protease)[7]. A typical example is complicated malaria, where in thrombocytopenic patients, vWF - ADAMTS13 imbalance maybe the pathogenic mechanism linking inflammation to

microvascular occlusion[8]. vWF levels also predict 28 day mortality in ICU patients with SIRS[9].

Similar vWF – ADAMTS13 imbalance occurs in cirrhosis, acute liver failure and when systemic inflammation is superimposed on cirrhosis. In patients with cirrhosis (of varied etiology, including viral and alcohol), vWF levels correlate with hepatic fibrosis[10], hepatic vein pressure gradient[10-12], and predict survival over next 2 - 3 years[11,12]. In acute liver failure, vWF-ADAMTS13 imbalance predicts survival[13]. vWF levels predict survival in patients with systemic inflammation superimposed on cirrhosis[14]. In addition, vWF-ADAMTS13 imbalance is noted in acute alcoholic hepatitis[15].

Although there is an increase in vWF levels in patients with cirrhosis, there may not be a commensurate increase in the vWF activity. This, hitherto unexplained phenomenon, may be one of the body's mechanisms to limit propensity of widespread thrombotic events in these patients[13]. ADAMTS13 regulates vWF multimer fraction, limiting the biological activity of vWF, and a decrease in ADAMTS13 concentration and activity may exacerbate the imbalance. Role of other vWF cleaving proteases in health and disease has not been well studied[13].

We hypothesized that systemic inflammation in ACLF will further activate the endothelium and elevate plasma vWF levels, increase platelet microthombi formation in affected organs, reduce organ perfusion and potentiate organ failure.

Prognostic significance of vWF levels in ACLF has not been studied.

The objectives of this study were

1. To document plasma vWF levels and correlate these with organ failure, liver disease severity, sepsis and SIRS in ACLF patients.
2. To analyse plasma vWF levels as predictors of in – hospital survival in ACLF patients.
3. To compare plasma vWF – ADAMTS13 balance in ACLF patients; in compensated cirrhosis patients, who did not have ACLF; and in healthy volunteers.

Materials and Methods :

From October 2014 to March 2015, consecutive adult patients with presentation as ACLF (as per APASL definition)[16], admitted in our department were prospectively recruited for this study after obtaining their informed consent.

Patients with hepatocellular carcinoma or portal vein thrombosis and those unwilling to participate were excluded from this study. Pregnant women and children were also excluded.

All patients underwent routine clinical examination and laboratory assessment. Underlying chronic liver disease was diagnosed based on clinical, biochemical, radiological and/or histological features. Assessment for causes of acute hepatic insult and of underlying chronic liver disease (e.g. alcohol, hepatotropic viruses, use of hepatotoxic drugs, autoimmune hepatitis, etc.) was done.

Assays for plasma von Willebrand factor : As per pre-specified study protocol, all study patients underwent assays for plasma vWF antigen and activity on Day 1 and Day 3 of hospital stay. For vWF assays, blood was collected using 0.109 M citrate anticoagulant and centrifuged at 2500 g

for 15 minutes at 4^0C. The separated plasma were aliquoted and stored frozen at - 80^0C until assay.

vWF antigen was measured using an ELISA kit (quantitative ELISA) as per manufacturer's instructions (Zymutest vWF Cat #RK 030A Hyphen BioMed, France). Collagen binding activity of vWF was measured by a similar method (Zymutest vWF:CBA Cat #RK 038A Hyphen BioMed, France) using microwells coated with fibrillar collagen types I and III[17]. A second order polynomial standard curve was used to obtain vWF antigen level as well as activity. In patients with high vWF levels, samples were pre-diluted (1 in 10) for the assays. Normal values for both plasma vWF antigen and activity were 50 % to 160 %. Specific vWF activity was calculated as ratio of vWF activity : vWF antigen.

Assay for plasma ADAMTS13 activity :

ADAMTS13 activity was estimated on Day 1 in all ACLF study patients on citrated platelet-poor plasma by an in-house collagen binding assay as previously described[18]. Normal range of ADAMTS13 activity was 55%-160%.

Plasma vWF – ADAMTS13 balance in ACLF, compensated cirrhosis and healthy volunteers :

We compared vWF – ADAMTS13 balance in ACLF patients, patients with Hepatitis B / C related compensated cirrhosis (none were in ACLF as per APASL criteria[16]) and in healthy volunteers. vWF:ADAMTS13 ratio was calculated by dividing Day 1 vWF activity by Day 1 ADAMTS13 activity.

Assessment of organ failure, liver disease severity, sepsis and SIRS in ACLF patients : Sequential organ failure (SOFA) score[19] (to assess organ failure), model for end-stage liver disease (MELD) score and ACLF grade (as per EASL-CLIF (Chronic Liver Failure) consortium

definition) (to assess liver disease severity) were calculated on Day 1 of hospital stay. Presence of SIRS[20]and sepsis[21] was assessed as per standard definition.

Incidence of new onset acute kidney injury and/or hepatic encephalopathy was documented on a daily basis during hospitalization.

Follow up and study outcome parameters in ACLF patients : All ACLF patients received standard medical treatment (no patient was treated with plasma exchange or N-acetyl cysteine) and were followed up daily. Study outcome (in-hospital transplant-free survival) was classified as discharge from hospital alive (in stable condition) or composite poor outcome (death / discharge in terminal condition / liver transplant).

Statistical analysis : Continuous variables were expressed as mean with standard deviation or median with range. Discrete variables were expressed as numbers and percentage. Continuous variables were compared by Mann Whitney U test / Wilcoxon sign rank and discrete variables by chi square test or Fischer's exact test, as relevant. Bi-variate correlation was assessed by Spearman correlation coefficient. Multivariate logistic regression was done to assess independent factors affecting survival in patients with ACLF. Univariate ordinal regression was done to analyse the ability of variables to predict baseline grade of ACLF (as per EASL-CLIF grading). Receiver operating characteristic (ROC) curve was used to assess sensitivity and specificity of plasma vWF as predictor of composite poor outcome. Assuming a 30% mortality rate in patients admitted to hospital with ACLF (audit estimates), we calculated that a sample size of 50 patients would allow us to evaluate role of vWF as a predictor, independent of MELD score, of in-hospital mortality. SPSS version 15 was used for statistical analysis and a two-sided p-value of <0.05 was considered as significant.

The study was approved by the institutional review board and ethics committee.

Results

Of the 50 ACLF patients studied, 29 (58%) were discharged in a stable condition while 21 (42%) had composite poor outcome - 10 died (hospital stay: 7, 2-12 days), 9 were discharged in terminal condition (hospital stay: 6, 2-11 days) and 2 underwent liver transplantation (hospital stay prior to transplant: 8, 5-11 days).

Baseline demographics and relevant laboratory data are depicted in Table 1. All ACLF study patients were in Child's class C at admission. Alcohol was the most common cause of chronic damage and of acute insult in ACLF patients. Other causes of chronic liver damage were - hepatitis B (5), cryptogenic (3), autoimmune (2) and non-alcoholic fatty liver disease (1). Other causes of acute insult were cryptogenic (6), hepatitis E (3), autoimmune flare (2), hepatitis B (1) and swine flu (1).

With increasing ACLF grade on Day 1 of hospital stay, MELD score as well as the proportion of patients with composite poor outcome increased (Table 2). New onset renal failure / encephalopathy were more common in ACLF patients with composite poor outcome (n=7) when compared to patients who were discharged in a stable state (n=2; p-value : 0.025).

Plasma vWF level on Day 1 of hospital stay (Figure 1) :

Day 1 plasma vWF antigen (725%, 212%-1347%; median, range) and activity (534%, 97%-1157%) were elevated in 50 ACLF patients studied. Day 1 plasma vWF antigen was higher in patients with composite poor outcome (742%, 264%-1347%) when compared to patients

discharged in stable condition (699%, 212%-1249%; p-value: 0.135). Day 1 plasma vWF activity was also significantly higher in patients with composite poor outcome (632%, 119%-1157%) when compared to patients discharged in stable condition (490% , 97%-986%; p-value : 0.025).

Plasma vWF level on Day 3 of hospital stay :

Day 3 plasma vWF antigen and activity remained elevated (712%, 279%-1411%; median range and 475%, 100%-1304% respectively) in 42 ACLF patients studied. There was no difference in plasma vWF antigen (746%, 326%-1157% v/s 689%, 279%-1411%; p-value : 0.6) and activity (457%, 244%-1334% v/s 497%, 100%-1304%; p-value : 0.916) in patients with composite poor outcome compared to those discharged in stable condition.

The interval change in plasma vWF antigen and activity over 3 days (Day 1 to Day 3 of hospital stay) was not significantly different in patients with composite poor outcome as compared to patients discharged in stable condition.

Correlation of Day 1 plasma vWF level with organ failure (SOFA score), liver disease severity (MELD score, ACLF grade), sepsis and SIRS in ACLF patients :

There was a moderate but significant positive correlation of Day 1 SOFA score with Day 1 vWF antigen (ρ=0.35; p-value : 0.02) and with Day 1 vWF activity (ρ=0.4; p-value : 0.002). There was a moderate, but significant positive correlation of Day 1 MELD score with Day 1 vWF antigen (ρ=0.25; p-value : 0.09) and also with Day 1 vWF activity (ρ=0.31; p-value : 0.03).

With increasing grade of ACLF on Day 1, there was a trend to increase in Day 1 vWF antigen and significant increase in Day 1 vWF activity. (Table 2)

Neither vWF antigen nor activity showed any correlation with baseline SIRS / sepsis nor with new onset kidney injury and hepatic encephalopathy (Table 3). Neither vWF antigen nor activity on Day 1 had any significant correlation with platelet counts, nor with alcohol as an etiology of acute insult (data not shown).

vWF antigen showed excellent and statistically significant correlation with vWF activity in all ACLF patients (ρ=0.85; p-value : <0.001), and also in ACLF patients with SIRS (ρ=0.84; p-value : <0.001)

Plasma vWF level as predictor of in-hospital survival :

On multivariate logistic regression analysis, adjusting for MELD score, Day 1 vWF activity showed a trend towards prediction of composite poor outcome [adjusted hazard ratio : 1.002; 95% CI: 1-1.005; p-value : 0.1].

Area under ROC curve (AUROC) for Day 1 plasma vWF antigen to predict composite poor outcome of hospital stay was 0.63 (95% CI: 0.47-0.8) and for vWF activity was 0.68 (95% CI: 0.52-0.84). AUROC for Day 1 MELD score and SOFA score to predict composite poor outcome was 0.74 (95% CI: 0.6-0.89) and 0.72 (95% C.I: 0.6-0.8) respectively. There was no statistical difference between AUROC of MELD score and vWF activity to predict composite poor outcome (p-value : 0.4). For Day 1 vWF activity the optimal cutoff for predicting composite poor outcome, as disclosed by Youden index, was 712% (sensitivity: 48% and specificity: 86%).

Table 4 describes the sensitivity, specificity, predictive values and likelihood ratios for various cut-offs of Day 1 vWF activity in predicting in - hospital survival.

Correlation of day 1 plasma ADAMTS13 activity with in-hospital survival in ACLF patients :

Day 1 ADAMTS13 activity was similar in ACLF patients with composite poor outcome (n=21, 42%,11%-120%; median, range) and in ACLF patients who were discharged in stable condition (n=29, 58%, 16%-125%; p-value: 0.11). There was a significantly higher day 1 vWF:ADAMTS13 activity ratio in ACLF patients with composite poor outcome (19, 1.4 – 96.4) as compared to patients who were discharged in stable state (8.5, 1.2 – 42.9; p-value : 0.03).

Plasma vWF-ADAMTS13 balance in ACLF patients as compared to compensated cirrhosis patients and healthy volunteers :

Figure 2 reflects the vWF antigen and activity in ACLF patients as compared 20 patients with compensated cirrhosis (age : 47 years, 23-64 years ; male : 14; hepatitis B related : 10 patients, hepatitis C related : 10 patients ; Child's class: A-9, B-5, C-5; MELD score: 10, 7-24) and 19 healthy volunteers (age:33 years, 27-65 years; median, range; male:16).

vWF antigen in ACLF patients (725 %, 212%-1347%; median, range) was significantly higher than in patients with Hepatitis B / C related cirrhosis (332%, 81%-785%) and in healthy volunteers (85%, 46%-128%; p-value < 0.001).

Similarly vWF activity was significantly higher in ACLF patients (534%, 97%-1157%) as compared patients with Hepatitis B / C related cirrhosis (275%, 80%-860%) and healthy volunteers (89%, 45%-130%; p-value < 0.001).

Specific vWF activity was significantly lower in ACLF patients (0.77, 0.15-1.5; median, range) than healthy volunteers (0.98, 0.62-1.9) and patients with compensated cirrhosis (0.9, 0.5-1.2; p-value < 0.001).

Day 1 plasma ADAMTS13 activity was significantly lower in 50 ACLF patients (47.5%, 11%-125%; median, range) as compared to 19 healthy volunteers (98.5%, 55%-122%; p-value<0.001) and 20 patients with compensated cirrhosis (96.5%, 27%-127%; p-value < 0.001).

Ratio of vWF activity: ADAMTS13 activity (on Day 1) was significantly higher in ACLF patients (11.2, 1.2-96.4; median, range) as compared to patients with compensated cirrhosis (3.3, 0.7-28.1, p-value : 0.01) and healthy volunteers (0.9, 0.4-2.4; p-value < 0.001).

Discussion :

We document markedly elevated plasma vWF antigen (7 fold median increase) and activity (5 fold median increase) on Day 1 and Day 3 in ACLF patients. vWF antigen and activity levels were 2 fold higher in ACLF patients when compared to compensated cirrhosis patients.

Of the different vWF assays done in ACLF patients, vWF activity on Day 1 was the best predictor of composite poor outcome at the end of hospital stay, with vWF activity level of > 1000 % having 100% positive predictive value (Table 4). Similarly, vWF activity on Day 1 correlated better with liver disease severity (MELD score, ACLF grade) and organ failure

(SOFA score) on Day 1 than vWF antigen on Day 1; in contrast, neither vWF antigen nor activity correlated with platelet count, sepsis or SIRS on Day 1 nor with new onset renal failure or hepatic encephalopathy during hospital stay.

Though all 50 ACLF patients studied had marked elevation of vWF levels, 9 (18%) patients did not fulfill criteria for SIRS and 30 (60%) did not have sepsis (Table 3). As APASL criteria for ACLF provides definition of ACLF and not disease severity classification, we used three different severity scores – MELD score, SOFA score and EASL-CLIF grading to stratify patients. Our study protocol pre-specified composite poor outcome of hospital stay as death/ discharged in terminal state/ liver transplant. This was to account for terminally ill patients requesting discharge from hospital, which is a reality in many resource constrained settings in developing countries. Duration of jaundice and of 'liver failure' prior to admission were not documented.

Infusion of endotoxin to human volunteers induced systemic inflammation, thrombocytopenia, leukocytosis, high vWF and low ADAMTS13 levels at 4 and 24 hours; and ultra-large VWF multimers after 4 hours[22]. Similar vWF – ADAMTS13 imbalance occurred after Desmopressin infusion in healthy volunteers[23]. Marked elevation of vWF levels in ACLF patients in our study probably reflects an 'acute-on-chronic' pro-inflammatory milieu leading to endothelial activation by release of inflammatory mediators reported in ACLF[1]. As most patients with ACLF had SIRS at admission, we failed to demonstrate its correlation with raised vWF levels.

vWF – ADAMTS13 imbalance occurs in patients with advancing cirrhosis[24]; in contrast, this imbalance occurs in patients with non cirrhotic intrahepatic portal hypertension (NCIPH), who

have well preserved liver functions[25,26], suggesting that vWF – ADAMTS13 imbalance maybe a pathogenic mechanism of chronic portal microangiopathy which causes non cirrhotic intrahepatic portal hypertension[27]. As NCIPH is often labeled as 'cryptogenic' cirrhosis, we did not include cryptogenic cirrhosis as a disease control.

In our study, etiology of ACLF patients (most patients had alcohol as etiology of liver disease) was different from patients with compensated cirrhosis (hepatitis B and C related). This is a limitation of our study, but previous studies (which included patients with alcohol liver disease) have otherwise shown an increase in vWF proportional to disease and portal hypertension severity irrespective of the etiology[11,12]. We also did not observe the effect of etiology of acute insult (alcohol v/s others) on vWF levels in ACLF study patients.

Of the many vWF assays tested in patients with liver disease, vWF antigen level is the easiest and most commonly performed assay. N acetyl cysteine used to treat acute liver failure, can be a confounder in some vWF assays, as it reduces vWF multimer size and activity[28].

Increased vWF levels induce further platelet adhesion, despite reduced function of vWF molecule in patients with cirrhosis[29]. Specific vWF activity in the current study also shows reduced vWF function, despite increased vWF levels in compensated cirrhosis; this phenomenon is even more exaggerated in ACLF. This may be secondary to compensatory, but often unsuccessful, mechanisms trying to limit the harmful thrombogenic effects of increased vWF.

Exaggerated platelet aggregation secondary to ultra-large vWF multimers and microvascular occlusion could explain the prognostic significance of vWF in cirrhosis[11,12,14,30], in acute liver injury[13] and in ACLF (current study). The degree of vWF elevation (Table 5) probably reflects degree of endothelial activation and tendency for microvascular occlusion (and hence failure) of the liver and other organs affected and probably determines the length of survival in

these patients. Based on vWF levels, compared to endothelial 'activation' in compensated cirrhosis patients, endothelial 'hyperactivation' is seen in ACLF patients (Table 5).

While intrahepatic endothelial activation and microvascular occlusion may impede hepatic perfusion and contribute to liver failure and short term mortality in acute liver failure; it leads to formation of focal parenchymal extinction lesions and confluent fibrosis in the liver[31] and probably contributes to medium term mortality in cirrhosis. In ACLF, it is likely that both these processes are superimposed on each other.

In this study we found significantly reduced ADAMTS13 activity (as measured by collagen binding assay) in ACLF patients as compared to compensated cirrhosis and healthy controls. We did not estimate ADAMTS13 activity by FRET (fluorescence resonance transfer) to avoid confounding by raised serum bilirubin (present in all ACLF patients).

High vWF levels causing microvascular occlusion by exaggerated platelet adhesion onto activated endothelium causing organ failure typically occurs in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome[32]. Plasma exchange with fresh frozen plasma replacement dramatically reduced mortality in these conditions[33]. Removal of large volumes of plasma during plasma exchange non–selectively reduces many plasma proteins including vWF[34,35]. ADAMTS13 supplementation is provided by fresh frozen plasma infusion[36]. Apart from primary thrombotic microangiopathies[32,33], plasma exchange may also be beneficial in other syndromes associated with thrombocytopenia and vWF–ADAMTS13 imbalance[8,37-40].

ACLF (current study) and acute liver failure patients have thrombocytopenia associated with vWF-ADAMTS13 imbalance[13]. In hepatitis B related ACLF, addition of plasma exchange improved short term survival compared to treatment with nucleoside analogues alone[41-43].

High volume plasma exchange reduced multi-organ dysfunction and improved transplant free survival in acute liver failure patients[44]. vWF reduction (which interrupts excessive platelet adhesion, microvascular thrombosis and multi-organ failure) maybe one mechanism by which plasma exchange improves survival in ACLF and acute liver failure patients.

In ACLF and other thrombocytopenic conditions wherein vWF-rich activated endothelium entraps more platelets, it is logical to avoid platelet transfusions; when platelet transfusions are deemed necessary, it is better to transfuse fresh frozen plasma initially (which supplements ADAMTS13) followed by platelet transfusion[45,46].

Studies exploring the role of vWF in progression of liver disease, by measuring vWF in hepatic venous blood and liver tissue can be undertaken. Further studies of plasma vWF levels as a prognostic marker of short term mortality in larger number of ACLF patients are needed. Effect of plasma exchange and other vWF reducing treatments[47-49] needs to be studied in ACLF and in acute liver failure patients. In conclusion, ACLF is characterized by markedly raised plasma vWF levels. vWF levels correlate with organ failure, liver disease severity and predicts in–hospital survival in ACLF patients.

Financial Support : We gratefully acknowledge funding support received from Department of Science and Technology, Government of India (File No. EMR/2015/000570) and FLUID research funds, Christian Medical College, Vellore, India towards the conduct of this study.

Conflict of Interest: KSP, AG, GJA, AR, KAB, IM, UZ, KGS, EE, CEE declare that they have no conflict of interest.

Ethical approval: The study was performed in a manner to conform with the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.

Informed consent: Informed consent was obtained from all individual participants included in the study.

References:

1. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol. 2012 ; 57 : 1336-48.
2. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426-37
3. Angeli P, Rodríguez E, Piano S, Ariza X, Morando F, Solà E, et al. CANONIC Study Investigators of the EASL-CLIF Consortium. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut 2015;64:1616-22.
4. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. North American Consortium For The Study Of End-Stage Liver Disease NACSELD. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60:250-6.
5. Kim HY, Chang Y, Park JY, Ahn H Cho H, Han SJ, et al. Characterization of acute-on-chronic liver failure and prediction of mortality in Asian patients with active alcoholism. J Gastroenterol Hepatol. 2015. doi: 10.1111/jgh.13084. [Epub ahead of print]
6. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010;38 (2 Suppl): S35-42.
7. Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during

systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost. 2009;101:239-47

8. Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost. 2015;113:708-18.
9. Hyseni A, Kemperman H, de Lange DW, Kesecioglu J, de Groot PG, Roest M. Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome. Blood 2014;123:2153-6.
10. Maieron A, Salzl P, Peck-Radosavljevic M, Trauner M, Hametner S, Schöfl R, et al. Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther.2014;39:331-8.
11. La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011;60:1133-8.
12. Ferlitsch M, Reiberger T, Hoke M, , Salzl P, Schwengerer B, Ulbrich G, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012 ; 56 : 1439 - 47.
13. Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013;58:752-61.
14. Reuken PA, Kussmann A, Kiehntopf M, Budde U, Stallmach A, Claus RA, et al. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. Liver Int. 2015;35:37-45.

15. Uemura M, Fujimura Y, Matsuyama T, Matsumoto M, Ishikawa M, Ishizashi H, Kato S, Tsujimoto T, Fujimoto M, Yoshiji H, Morioka C, Fukui H. Potential role of ADAMTS13 in the progression of alcoholic hepatitis. Curr Drug Abuse Rev 2008;1:188-96
16. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8:453-71.
17. Brown JE, Bosak JO. An Elisa test for the binding of von Willebrand antigen to collagen. Thromb Res. 1986;43:303–311.
18. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF) - cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386-89.
19. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-10.
20. Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25:1789-95.

21. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580-637.

22. Reiter RA, Varadi K, Turecek PL, Jilma B, Knöbl P. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 2005;93:554-8.

23. Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood. 2003;101:946-8.

24. Uemura M, Fujimura Y, Matsumoto M, , Ishizashi H, Kato S, Matsuyama T, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99:1019-29.

25. Mackie I, Eapen CE, Neil D, Lawrie AS, Chitolie A, Shaw JC, Elias E. Idiopathic noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 deficiency. Dig Dis Sci. 2011;56:2456-65.

26. Goel A, Alagammai PL, Nair SC, , Mackie I, Ramakrishna B, Muliyil J, et al. ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension. Indian J Gastroenterol. 2014;33:355-63.

27. Goel A, Elias JE, Eapen CE, Ramakrishna B, Elias E. Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options. J Clin Exp Hepatol. 2014;4:247-56.

28. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121:593-603.

29. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53-61.
30. Eapen CE, Elias JE, Mackie I, Elias E. Prognostic significance of von willebrand factor in cirrhosis: a possible mechanism. Hepatology 2013;58:1189.
31. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995;21:1238-47.
32. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654-66.
33. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398-403.
34. Flaum MA, Cuneo RA, Appelbaum FR, Deisseroth AB, Engel WK, Gralnick HR. The hemostatic imbalance of plasma-exchange transfusion. Blood. 1979;54(3):694-702.
35. Lin SM , Yeh JH, Lee CC, Chiu HC. Clearance of fibrinogen and von Willebrand factor in serial double-filtration plasmapheresis. J Clin Apher. 2003;18(2):6770.
36. McLeod BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. Best Pract Res Clin Haematol. 2006;19(1):157-67.
37. Dahlan R, Sontrop JM, Li L, Ghadieh O, Clark WF. Primary and Secondary Thrombotic Microangiopathy Referred to a Single Plasma Exchange Center for Suspected Thrombotic Thrombocytopenic Purpura: 2000-2011. Am J Nephrol. 2015;41:429-37.

38. Eskazan AE, Salihoglu A. Treatment and Outcome of Primary and Secondary Thrombotic Microangiopathies. Am J Nephrol. 2015;41:427-8.
39. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043-9.
40. Deepanjali S, Naik RR, Mailankody S, Kalaimani S, Kadhiravan T. Dengue Virus Infection Triggering Thrombotic Thrombocytopenic Purpura in Pregnancy. Am J Trop Med Hyg. 2015; pii: 15-0326. [Epub ahead of print]
41. Yu JW, Sun LJ, Zhao YH, Li SC. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol. 2008;23:1242-9.
42. Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2015 [Epub ahead of print]
43. Qin G, Shao JG, Wang B, Shen Y, Zheng J, Liu XJ, et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore). 2014;93:e338. doi: 10.1097/MD.0000000000000338.
44. Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC,et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol. 2015. doi: 10.1016 / j.jhep.2015.08.018. [Epub ahead of print]

45. Eapen CE, Elias E, Goel A, John TJ. Hypothesis of mechanism of thrombocytopenia in severe dengue, providing clues to better therapy to save lives. Current Science 2015;108:168–9.
46. Ko S, Chisuwa H, Matsumoto M, Fujimura Y, Okano E, Nakajima Y. Relevance of ADAMTS13 to liver transplantation and surgery. World J Hepatol. 2015;7:1772-81.
47. Li GW, Rambally S, Kamboj J, , Reilly S, Moake JL, Udden MM, Mims MP. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion. 2014;54:1221-4.
48. Elias JE, Mackie I, Eapen CE, Chu P, Shaw JC, Elias E. Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency. J Hepatol. 2013;58:827-30.
49. Erpenbeck L, Demers M, Zsengellér ZK, Gallant M, Cifuni SM, Stillman IE, et al. ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy. J Am Soc Nephrol. 2015. pii: ASN.2014121165. [Epub ahead of print]

Table 1 : Baseline characteristics in ACLF patients

Parameter	**All ACLF patients (n=50)**	**Discharged alive (n=29)**	**Composite poor outcome (n=21)**	**p-value***
Age (years)	43.5 (28-64)	43 (28-64)	40 (30-58)	0.7
Sex (M:F)	45:5	26:3	19:2	1
Etiology of chronic liver disease (Alcohol : Hepatitis B : Others)	39 : 5 : 7	22 : 4 : 3	17 : 1 : 3	-
Acute insult (Alcohol : Viral : Others)	37 : 5 : 8	21 : 3 : 5	16 : 2 : 3	-
Serum bilirubin (mg/dl)	17.3 (5-37)	11.6 (5-33.4)	21.7 (5.1-37)	0.1
Serum creatinine (mg/dl)	1.4 (1-6)	1 (1-6)	2.2 (1-6)	0.005
Prothrombin time (INR)	2 (1.5-10)	1.9 (1.5-4.5)	2.2 (1.5-10)	0.293
Platelet counts ($x10^3/\mu L$)	93 (30-353)	92 (30-240)	96 (30-353)	1
MELD score	29 (17-49)	26 (17-49)	35 (22-47)	0.002
SOFA score	7 (4-14)	6 (4-14)	8 (4-14)	0.007
ACLF grading (Grade 0:1:2:3)	16:13:13:8	15:8:3:3	1:5:10:5	0.001
SIRS, n(%)	41 (82%)	24 (83%)	17(81%)	1.000
Sepsis, n(%)	20 (40%)	$15^{\#}$ (52%)	$5^{\$}$ (24%)	0.08
Duration of hospital stay (days)	6 (2-28)	7 (3-28)	5 (2-12)	0.08

All continuous variables are expressed as median (range) and categorical variables as numbers (percentage).

*Comparing 'Discharged alive' v/s 'Composite poor outcome'

Either culture positive from blood (4), ascitic fluid (3), urine (2) samples; and/or neutrophilic ascitic fluid suggesting spontaneous bacterial peritonitis (11).

$ Either culture positive from blood (2), ascitic fluid (2), urine(2) and/or neutrophilic ascitic fluid suggesting spontaneous bacterial peritonitis (3).

MELD : model for end stage liver disease; SOFA: sequential organ failure assessment; ACLF : acute-on-chronic liver failure; SIRS : systemic inflammatory response syndrome

Table 2: Liver disease severity (MELD score), plasma vWF levels (on Days 1 and 3 of hospital stay) and in - hospital survival in patients in different grades of ACLF.

	ACLF grades				p value*
	Grade 0 (n=16)	**Grade 1 (n=13)**	**Grade 2 (n=13)**	**Grade 3 (n=8)**	
Age (years)	41 (30-63)	49 (30-62)	41 (28-64)	40.5 (35-58)	0.75
MELD	23 (19-27)	29 (17-36)	37 (26-47)	41 (30-49)	<0.001
vWF antigen (Day 1)	690 (264-1082)	700 (212-1347)	686 (515-1338)	986 (742-1344)	0.09
vWF antigen (Day 3)	654 (301-1169)	640 (279-1411)	594 (334-998)	885 (702-1054)	0.5
vWF activity (Day 1)	491 (97-949)	468 (116-835)	532 (221-1090)	882 (676-11157)	0.02
vWF activity (Day 3)	466 (100-1247)	447 (132-1218)	441 (277-1304)	766 (713-904)	0.16
Platelets ($x10^3/\mu L$)	99 (39-243)	71 (30-225)	121 (30-353)	94 (35-198)	0.9
Composite poor outcome n (%)	1(6%)	5 (38.5%)	10 (76.9%)	5 (62.5%)	0.01

MELD : Model for end-stage liver disease; vWF : von-Willebrand factor.

*Univariate ordinal regression

Table 3: Comparing Day 1 plasma vWF levels in 50 ACLF patients as per presence of sepsis and systemic inflammatory response syndrome (SIRS) at presentation and as per new onset renal failure or encephalopathy which developed during hospital stay.

	SIRS			**Sepsis**			**New onset renal failure / encephalopathy**		
	Yes (n=41)	**No (n=9)**	**p-value**	**Yes (n=20)**	**No (n=30)**	**p-value**	**Yes (n=9)**	**No (n=41)**	**p-value**
Day 1 vWF antigen	725 (212-1347)	789 (264-1338)	1	696 (260-1249)	779 (212-1347)	0.3	955 (369-1347)	711 (212-1344)	0.4
Day 1 vWF activity	589 (97-1157)	522 (119-1090)	0.8	510 (97-1411)	564 (119-1157)	0.25	736 (221-835)	532 (97-1157)	0.7

Table 4: Plasma vWF activity on Day 1 as a predictor of in - hospital composite poor outcome (death/ transplant/ discharged in terminal condition) in ACLF patients

vWF activity	Composite poor outcome	Alive	Hazard ratio	Sensitivity	Specificity	NPV	PPV	NLR	PLR
>250%	19	23	2.5 (0.5-13.7)	0.9 (0.8-1)	0.2 (0.1-0.3)	0.8 (0.4-1)	0.5 (0.4-0.5)	0.46 (0.1-2.3)	1.1 (0.9-1.3)
<250%	2	6							
>500%	15	13	3.1 (0.9-10.2)	0.7 (0.5-0.9)	0.5 (0.4-0.7)	0.7 (0.6-0.9)	0.5 (0.4-0.7)	0.5 (0.2-1.1)	1.6 (0.9-2.5)
<500%	6	16							
>750%	8	3	5.3 (1.2-23.5)	0.4 (0.2-0.5)	0.9(0.8-1)	0.7(0.6-0.7)	0.7(0.4-0.9)	0.7(0.5-1)	3.7(1-16.6)
<750%	13	26							
>1000%	5	0	∞ (1.3-∞)	0.2(0.1-0.2)	1(0.9-1)	0.6(0.6-0.6)	1(0.5-0.9)	0.8(0.8-1)	∞ (1.3-∞)
<1000%	16	29							

NPV : negative predictive value, PPV : positive predictive value, NLR : negative likelihood ratio, PLR : positive likelihood ratio

Table 5. Plasma vWF levels as predictor of survival in different studies of patients with acute liver failure, ACLF and cirrhosis.

	ACLF (Present study)	Cirrhosis[11]	Cirrhosis[12]		Cirrhosis ± systemic inflammation[14]	Acute liver failure[13]
n	50	42	286		80	50
			189 (comp-ensated)	97 (decomp-ensated)		
vWF antigen	725% (212 – 1347)%	222 ±17 %	264% (194-345) %	394% (303-505)%		547% (242-1420)%
Follow up	8 (3-28) days	24 (1-24) months	33 (30-36) months		2 years	
Predicting outcome						
vWF antigen	AUC: 0.63 (95% CI: 0.47-0.8)	AUC : 0.74* (95% CI: 0.58 – 0.9)	AUC : 0.71 (95% CI: 0.65-0.77)*		AUC : 0.78[#] (95% CI: 0.66–0.91)	NS[#]

*Predicting death / transplant / portal hypertension related event

#Predicting transplant free survival

AUC : area under the curve ; NS : not significant

Figure Legends :

Figure 1 : Comparing Day 1 plasma vWF antigen and activity in ACLF patients who were discharged from hospital in stable state to those with composite poor outcome.

Figure 2 : Plasma vWF antigen and activity in ACLF patients as compared to healthy volunteers and patients with hepatitis B/C related compensated cirrhosis.


1500
1000
500
0
Percentage
Day 1 vWF antigen
p-value:0.135
Day 1 vWF activity
p-value:0.025
Alive
Composite poor outcome
Alive
Composite poor outcom

Figure 1


vWF antigen
vWF activity
p-value<0.001
p-value<0.001
Percentage
1400
1200
1000
800
600
500
400
300
200
100
100
50
0
Healthy
Cirrhosis
ACLF
Healthy
Cirrhosis
ACLF

Figure 2